[A new beta 1-receptor blocker in the therapy of essential hypertension and angina pectoris].
In 242 patients with hypertension and/or angina pectoris, a new cardioselective betablocker without ISA, bisoprolol (Concor), was tested. The average mean value of 168/102 mm Hg was lowered in the 174 hypertensive patients by a systolic value of 17 and a diastolic value of 11 mm Hg. A normal diastolic pressure of 95 mm Hg or below was attained within 4 weeks in 73% of patients. Angina pectoris improved from 7 attacks per week before treatment to 3 attacks after 2 weeks; patients with additional hypertension showed a further improvement after another two weeks to an average of 1.7 attacks per week. Side effects were most frequently dizziness, headache and fatigue and also a few patients with gastrointestinal symptoms, an unusual side effect with this treatment. The results show the effective antihypertensive and antianginal action of bisoprolol in a large group of outpatients.
Burkart
F
F
Department für Innere Medizin, Universitätskliniken Kantonssipital Basel.
Stamm
G
G
Witassek
F
F
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy*; D017298:Bisoprolol; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D017298:Bisoprolol
Ein neuer beta 1-Rezeptoren-Blocker in der Therapie der essentiellen Hypertonie und der Angina pectoris.